BIAF
bioAffinity Technologies, Inc. Common Stock
stockNASDAQ
addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.93 | 2026-11-04 | -21.84% | -0.004 |
| 1M | 3.90 | 2026-10-12 | -41.28% | 0.867 |
| 3M | 7.29 | 2026-08-11 | -68.59% | 1.882 |
| 6M | 29.55 | 2026-05-11 | -92.25% | 1.722 |
| 1Y | 32.40 | 2025-11-11 | -92.93% | 2.126 |
| 2Y | 598.50 | 2024-11-11 | -99.62% | — |
| 5Y | 3,735.00 | 2022-09-01 | -99.94% | 1.410 |
bioAffinity Technologies, Inc. Common Stock (NASDAQ:BIAF) stock price today is $2.29, and today's volume is 22,356. BIAF is down 4.184% today. The 30 day average volume is 1.34M. BIAF market cap is $1.38M with 600,736 shares outstanding.